153 related articles for article (PubMed ID: 10403914)
1. Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes.
Stosic-Grujicic S; Dimitrijevic M; Bartlett R
Clin Exp Immunol; 1999 Jul; 117(1):44-50. PubMed ID: 10403914
[TBL] [Abstract][Full Text] [Related]
2. Pentoxifylline prevents autoimmune mediated inflammation in low dose streptozotocin induced diabetes.
Stosić-Grujicić SD; Maksimović DD; Stojković MB; Lukić ML
Dev Immunol; 2001; 8(3-4):213-21. PubMed ID: 11785671
[TBL] [Abstract][Full Text] [Related]
3. Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes.
Miljkovic D; Samardzic T; Mostarica Stojkovic M; Stosic-Grujicic S; Popadic D; Trajkovic V
Brain Res; 2001 Jan; 889(1-2):331-8. PubMed ID: 11166726
[TBL] [Abstract][Full Text] [Related]
4. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.
Jankovic V; Samardzic T; Stosic-Grujicic S; Popadic D; Trajkovic V
Cell Immunol; 2000 Feb; 199(2):73-80. PubMed ID: 10698616
[TBL] [Abstract][Full Text] [Related]
5. Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice.
Karabatas LM; Pastorale C; de Bruno LF; Maschi F; Pivetta OH; Lombardo YB; Chemes H; Basabe JC
Pancreas; 2005 May; 30(4):318-24. PubMed ID: 15841040
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes.
Stosic-Grujicic SD; Miljkovic DM; Cvetkovic ID; Maksimovic-Ivanic DD; Trajkovic V
J Autoimmun; 2004 Jun; 22(4):267-76. PubMed ID: 15120750
[TBL] [Abstract][Full Text] [Related]
7. Antidiabetogenic effect of pentoxifylline is associated with systemic and target tissue modulation of cytokines and nitric oxide production.
Stosić-Grujicić S; Maksimović D; Badovinac V; Samardzić T; Trajković V; Lukić M; Mostarica Stojković M
J Autoimmun; 2001 Feb; 16(1):47-58. PubMed ID: 11221996
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction.
Hoskin DW; Taylor RM; Makrigiannis AP; James H; Lee TD
Int J Immunopharmacol; 1998 Sep; 20(9):505-13. PubMed ID: 9818794
[TBL] [Abstract][Full Text] [Related]
9. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice.
Stosic-Grujicic S; Cvetkovic I; Mangano K; Fresta M; Maksimovic-Ivanic D; Harhaji L; Popadic D; Momcilovic M; Miljkovic D; Kim J; Al-Abed Y; Nicoletti F
J Pharmacol Exp Ther; 2007 Mar; 320(3):1038-49. PubMed ID: 17148780
[TBL] [Abstract][Full Text] [Related]
10. [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].
Fang C; Zhou D; Zhan S; He Y; Lin Z; Huang C; Li J
Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):754-61. PubMed ID: 26693771
[TBL] [Abstract][Full Text] [Related]
11. Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide.
Stosic-Grujicic S; Dimitrijevic M; Bartlett RR
Transplant Proc; 1998 Dec; 30(8):4132-3. PubMed ID: 9865323
[No Abstract] [Full Text] [Related]
12. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.
Maksimovic-Ivanic D; Trajkovic V; Miljkovic DJ; Mostarica Stojkovic M; Stosic-Grujicic S
Clin Exp Immunol; 2002 Aug; 129(2):214-23. PubMed ID: 12165076
[TBL] [Abstract][Full Text] [Related]
13. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.
Herrmann ML; Schleyerbach R; Kirschbaum BJ
Immunopharmacology; 2000 May; 47(2-3):273-89. PubMed ID: 10878294
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
15. Effect of modified diabetic splenocytes on mice injected with multiple low-dose streptozotocin.
Pastorale C; Arata M; Caminos A; Bruno L; Basabe J; Chemes H
Exp Biol Med (Maywood); 2002 Apr; 227(4):282-9. PubMed ID: 11910051
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
17. Temporal relationship between immune cell influx and the expression of inducible nitric oxide synthase, interleukin-4 and interferon-gamma in pancreatic islets of NOD mice following adoptive transfer of diabetic spleen cells.
Reddy S; Karanam M; Krissansen G; Nitschke K; Neve J; Poole CA; Ross JM
Histochem J; 2000 Apr; 32(4):195-206. PubMed ID: 10872884
[TBL] [Abstract][Full Text] [Related]
18. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide).
Richard M; Hoskin DW
Int J Immunopharmacol; 1998; 20(4-5):241-52. PubMed ID: 9730259
[TBL] [Abstract][Full Text] [Related]
20. Leflunomide-mediated suppression of antiviral antibody and Tcell responses: differential restoration by uridine.
Pinschewer DD; Ochsenbein AF; Fehr T; Zinkernagel RM
Transplantation; 2001 Aug; 72(4):712-9. PubMed ID: 11544436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
